PARP1 and prostate carcinoma: Our and others’ prior work have shown that HR-deficient ovarian, breast, and prostate cancers are exquisitely sensitive to platinum agents and PARP inhibition11,13,22–24, and we hypothesized that gastric cancers deficient in HR (or with high HRD scores) would be more sensitive to platinum agents and PARP inhibition.